Hi @mave1979—I’m truly sorry your mum is facing this. Everyone here is happy to share personal experiences, but the best medical guidance will always come from her oncology team.

In my own case, my non-small-cell lung cancer (NSCLC) showed high PD-L1, yet that didn’t influence treatment because I carry an EGFR Exon 19 mutation; targeted therapy took priority. When doctors move straight to immunotherapy, it often means no targetable mutation was found. Immunotherapy tends to work best in tumours linked to a smoking history, though researchers are still uncovering exactly why.

A quick point of terminology: if scans show a lung-cancer deposit in the pancreas, it’s still lung cancer—it’s just “metastatic” (a spread) rather than a new pancreatic cancer. The same word “met” can also refer to MET-gene mutations, so the jargon can get confusing.

For context, my own lung cancer spread to the brain. That didn’t turn it into brain cancer; it remained lung cancer and followed its own treatment rules. That distinction matters, because prognosis and treatment options differ considerably across cancer types—and metastatic lung cancer now has far more options than primary pancreatic or most primary brain cancers.

Keep asking the oncologist about next steps, mutation testing, and why a particular therapy was chosen. And remember, many of us continue to work, enjoy family life, and achieve milestones during treatment—you and your mum can, too. We’re all here cheering you on.